What's in Shanghai Junshi Bioscience Co., Ltd.'s pipeline?

Shanghai Junshi Bioscience Co., Ltd. has 24 drugs in our index: 0 marketed, 0 filed, 9 in Phase 3, 5 in Phase 2, 10 in Phase 1.

Which companies overlap with Shanghai Junshi Bioscience Co., Ltd.'s portfolio?

Top competitors by shared drug class: Sun Yat-sen University, Jiangsu HengRui Medicine Co., Ltd., Federation Francophone de Cancerologie Digestive, Merck Sharp & Dohme LLC, Celltrion.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/shanghai-junshi-bioscience-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Shanghai Junshi Bioscience Co., Ltd. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Shanghai Junshi Bioscience Co., Ltd. pipeline: 0 marketed, 0 filed, 9 Phase 3, 5 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 9 Phase 3 5 Phase 2 10 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Bendamustine or gemcitabine	Bendamustine or gemcitabine	phase 3	Chemotherapy combination (alkylating agent + nucleoside analog)	DNA (bendamustine: alkylating agent; gemcitabine: ribonucleotide reductase inhibitor)	Oncology
Placebo for Tifcemalimab	Placebo for Tifcemalimab	phase 3
JS004 in combination with toripalimab	JS004 in combination with toripalimab	phase 3	CTLA-4 inhibitor (in combination with PD-1 inhibitor)	CTLA-4	Oncology
Oxaliplatin for injection	Oxaliplatin for injection	phase 3	Platinum-based chemotherapy	DNA	Oncology
Tifcemalimab injection	Tifcemalimab injection	phase 3	PD-1 inhibitor	PD-1	Oncology
Placebo for toripalimab	Placebo for toripalimab	phase 3			Oncology
JS002	JS002	phase 3	PD-1 inhibitor	PD-1	Oncology
JS107 for Injection	JS107 for Injection	phase 3	PD-L1 inhibitor	PD-L1	Oncology
Cisplatin for Injection / Carboplatin Injection	Cisplatin for Injection / Carboplatin Injection	phase 3	Platinum-based chemotherapy agent	DNA	Oncology

Therapeutic area mix

Oncology · 9
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Sun Yat-sen University · 4 shared drug classes
Jiangsu HengRui Medicine Co., Ltd. · 4 shared drug classes
Federation Francophone de Cancerologie Digestive · 3 shared drug classes
Merck Sharp & Dohme LLC · 3 shared drug classes
Celltrion · 2 shared drug classes
Akeso · 2 shared drug classes
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 shared drug classes
AstraZeneca · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Shanghai Junshi Bioscience Co., Ltd.:

Cite this brief

Drug Landscape (2026). Shanghai Junshi Bioscience Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shanghai-junshi-bioscience-co-ltd. Accessed 2026-06-10.